KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to -$3.0 billion.

  • Takeda Pharmaceutical's Operating Expenses rose 292.18% to -$3.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.0 billion, marking a year-over-year decrease of 43433.76%. This contributed to the annual value of $5.3 billion for FY2025, which is 703.54% down from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Operating Expenses stood at -$3.0 billion, which was up 292.18% from -$6.6 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Operating Expenses ranged from a high of $14.3 billion in Q1 2024 and a low of -$6.6 billion during Q3 2024
  • Its 5-year average for Operating Expenses is -$1.2 billion, with a median of -$3.1 billion in 2022.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Operating Expenses crashed by 12306.37% in 2022, and later soared by 56002.72% in 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Operating Expenses (Quarter) stood at -$3.2 billion in 2021, then increased by 2.2% to -$3.1 billion in 2022, then dropped by 3.09% to -$3.2 billion in 2023, then grew by 3.86% to -$3.1 billion in 2024, then rose by 2.92% to -$3.0 billion in 2025.
  • Its last three reported values are -$3.0 billion in Q4 2025, -$6.6 billion for Q3 2025, and -$2.8 billion during Q2 2025.